Questions About Cancer? 1-800-4-CANCER
  • Print
  • Facebook
  • Twitter
  • Google+
  • Pinterest

NCI Drug Dictionary


nelipepimut-S plus GM-CSF vaccine 
A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the HER2 protein (E75 peptide) and combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activity. Upon intradermal injection, nelipepimut-S plus GM-CSF vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cell types. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF potentiates the antitumor immune response. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms:E75 Plus GM-CSF
E75 vaccine plus GM-CSF
HLA A2/A3–restricted HER-2/neu peptide vaccine plus GM-CSF
nelipepimut-S plus sargramostim
NeuVax Plus GM-CSF